To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Cardiovascular Diseases: Health Services
Monday 26th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 9 September (HL2184), what steps they are taking to improve outcomes for people currently living with peripheral arterial disease, in addition to action on the cardiovascular risk factors associated with the disease.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England does not hold a specific, routinely produced dataset providing the number of major lower-limb amputations, surgical bypass procedures, and endovascular revascularisation procedures for patients with peripheral arterial disease (PAD), broken down by integrated care board and year.

Published information on vascular procedures is available through the National Vascular Registry. This is available through the GOV.UK website.

NHS England commissions vascular arterial care from a number of specialist centres to ensure appropriate management of PAD at a national level. The Vascular Disease Clinical Reference Group works closely with Getting It Right First Time and the respective professional societies to review patient outcomes and support commissioned providers in the delivery of high-quality care for patients.

The Department has published a new Cardiovascular Disease Modern Service Framework, which prioritises ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care, supporting consistent and equitable access across the cardiovascular disease pathway.


Written Question
Cardiovascular Diseases: Health Services
Monday 26th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many (1) major lower-limb amputations, (2) surgical bypass procedures, and (3) endovascular revascularisation procedures, including angioplasty, were carried out in England on patients with peripheral arterial disease in each of the last three years for which data is available, broken down by integrated care board.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England does not hold a specific, routinely produced dataset providing the number of major lower-limb amputations, surgical bypass procedures, and endovascular revascularisation procedures for patients with peripheral arterial disease (PAD), broken down by integrated care board and year.

Published information on vascular procedures is available through the National Vascular Registry. This is available through the GOV.UK website.

NHS England commissions vascular arterial care from a number of specialist centres to ensure appropriate management of PAD at a national level. The Vascular Disease Clinical Reference Group works closely with Getting It Right First Time and the respective professional societies to review patient outcomes and support commissioned providers in the delivery of high-quality care for patients.

The Department has published a new Cardiovascular Disease Modern Service Framework, which prioritises ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care, supporting consistent and equitable access across the cardiovascular disease pathway.


Written Question
Cardiovascular Diseases: Health Services
Monday 26th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what the most recent referral-to-treatment waiting time statistics are for the vascular surgery treatment function in England, broken down by integrated care board.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England does not hold a specific, routinely produced dataset providing the number of major lower-limb amputations, surgical bypass procedures, and endovascular revascularisation procedures for patients with peripheral arterial disease (PAD), broken down by integrated care board and year.

Published information on vascular procedures is available through the National Vascular Registry. This is available through the GOV.UK website.

NHS England commissions vascular arterial care from a number of specialist centres to ensure appropriate management of PAD at a national level. The Vascular Disease Clinical Reference Group works closely with Getting It Right First Time and the respective professional societies to review patient outcomes and support commissioned providers in the delivery of high-quality care for patients.

The Department has published a new Cardiovascular Disease Modern Service Framework, which prioritises ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care, supporting consistent and equitable access across the cardiovascular disease pathway.


Written Question
Semaglutide
Monday 19th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they are satisfied that all integrated care boards and other relevant NHS commissioning bodies have enabled GP practices to prescribe and administer semaglutide to patients newly eligible under recent NICE recommendations; and whether implementation has been completed within the three-month period ordinarily allowed for the funding and commissioning of technologies recommended by NICE.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England publicly announced the planned rollout and eligibility criteria for semaglutide for cardiovascular risk reduction, which are available on the NHS.UK website, and has supported implementation through national commercial and financial arrangements. NHS England does not currently hold a validated national estimate of the number of patients who have commenced treatment specifically under this indication, or of the implementation status for every general practice or integrated care board.


Written Question
Semaglutide
Monday 19th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to publicise the availability of semaglutide injections for the prevention of heart attacks and strokes among eligible patients with cardiovascular disease, following the publication of guidance from NICE and the planned rollout of the treatment by NHS England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England publicly announced the planned rollout and eligibility criteria for semaglutide for cardiovascular risk reduction, which are available on the NHS.UK website, and has supported implementation through national commercial and financial arrangements. NHS England does not currently hold a validated national estimate of the number of patients who have commenced treatment specifically under this indication, or of the implementation status for every general practice or integrated care board.


Written Question
Semaglutide
Monday 19th October 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the progress of the rollout of semaglutide to the additional categories of patients recently made eligible for treatment; and whether they have estimated the number of patients who have taken up treatment under the expanded eligibility criteria.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England publicly announced the planned rollout and eligibility criteria for semaglutide for cardiovascular risk reduction, which are available on the NHS.UK website, and has supported implementation through national commercial and financial arrangements. NHS England does not currently hold a validated national estimate of the number of patients who have commenced treatment specifically under this indication, or of the implementation status for every general practice or integrated care board.


Written Question
Cardiovascular Diseases: Health Services
Wednesday 9th September 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they plan to include specific actions on the prevention, diagnosis and treatment of peripheral arterial disease in the delivery plans supporting the Cardiovascular Disease Modern Service Framework, including in any future iterations of the framework.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recently published the Cardiovascular Disease Modern Service Framework (CVD MSF), which sets out priorities, challenge areas, and a future vision for the health and care system to accelerate progress on the ambition to reduce premature deaths from heart disease and stroke by 25% within the next decade.

Many of the risk factors for cardiovascular disease also increase the risk of peripheral arterial disease (PAD) and therefore action on the following priorities will also improve PAD outcomes:

  • improving smoking cessation;

  • finding people with undiagnosed atrial fibrillation, albuminuria, high blood pressure, high cholesterol, diabetes, excess weight, and reduced kidney function; and

  • treating people with high blood pressure or cholesterol to evidence-based targets.

Alongside the priority actions, the CVD MSF sets out challenge areas where more evidence or innovations are needed to drive improvements. Further developing diagnostic capabilities to better detect and treat cardiovascular-kidney-metabolic (CVKM) risk, including for conditions like PAD, is named as one of these challenge areas.

Finally, the CVD MSF sets out a longer-term vision for more stratified, personalised, and holistic CVKM risk assessment. Subject to the evidence, resources, and agreement, this could include improving the detection and management of PAD.


Written Question
Peripheral Arterial Disease: Health Services
Wednesday 9th September 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, with reference to the Cardiovascular Disease Modern Service Framework published on 7 July, how they intend to address peripheral arterial disease in their delivery plan due to be published later this year.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recently published the Cardiovascular Disease Modern Service Framework (CVD MSF), which sets out priorities, challenge areas, and a future vision for the health and care system to accelerate progress on the ambition to reduce premature deaths from heart disease and stroke by 25% within the next decade.

Many of the risk factors for cardiovascular disease also increase the risk of peripheral arterial disease (PAD) and therefore action on the following priorities will also improve PAD outcomes:

  • improving smoking cessation;

  • finding people with undiagnosed atrial fibrillation, albuminuria, high blood pressure, high cholesterol, diabetes, excess weight, and reduced kidney function; and

  • treating people with high blood pressure or cholesterol to evidence-based targets.

Alongside the priority actions, the CVD MSF sets out challenge areas where more evidence or innovations are needed to drive improvements. Further developing diagnostic capabilities to better detect and treat cardiovascular-kidney-metabolic (CVKM) risk, including for conditions like PAD, is named as one of these challenge areas.

Finally, the CVD MSF sets out a longer-term vision for more stratified, personalised, and holistic CVKM risk assessment. Subject to the evidence, resources, and agreement, this could include improving the detection and management of PAD.


Written Question
General Practitioners: Internet
Monday 6th July 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, in light of the rule changes around GP appointment requests introduced in 2025, what percentage of GP practices in England are currently offering online bookings for GP appointments; and why the rule changes have not yet been fully actioned by some GP practices.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

General practices (GPs) are independent business that hold contracts with the National Health Service to perform essential services to the public. We require practices to provide online consultation tools. From 1 October 2025, GPs have been required to offer access to online services throughout core hours, 8:00am to 18:30pm, bringing online access in line with walk-in and phone access. This change aims to improve patient access, reduce long phone queues, and help GPs manage demand more effectively.

NHS England collects data on GP appointments, online consultation submissions, and cloud-based telephony. This data shows that 99% of practices have reported having an online consultation system in place. Where a practice does not comply with these contractual requirements, it may be in breach of contract. Patients who have concerns should contact their practice in the first instance, or raise the matter with their local integrated care board.


Written Question
Obesity: Drugs
Tuesday 30th June 2026

Asked by: Lord Booth (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 10 June (HL543), whether those categories of patients now eligible to receive semaglutide by injection will also be eligible for orforglipron tablets on the same basis.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Orforglipron does not yet have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency, so it cannot currently be marketed in the United Kingdom. Any future licence would set out the condition it can be used for, and the recommended dosage. The National Institute for Health and Care Excellence (NICE) is responsible for making recommendations to the National Health Service on whether newly licensed medicines should be routinely funded, based on an assessment of their clinical and cost effectiveness. NICE has scheduled an appraisal of orforglipron for managing obesity or overweight with at least one weight-related co-morbidity, in anticipation of a UK marketing authorisation being granted. It will aim to publish guidance as close as possible to the expected licensing date, with final guidance currently expected in November 2026.